Abstract |
There is an unmet medical need for vaccines to prevent dengue. V180 is an investigational recombinant subunit vaccine that consists of truncated dengue envelope proteins (DEN-80E) for all 4 serotypes. Three dosage levels of the tetravalent DEN-80E antigens were assessed in a randomized, placebo-controlled, Phase I dose-escalation, first-in-human proof-of-principle trial in healthy, flavivirus-naïve adults in Australia (NCT01477580). The 9 V180 formulations that were assessed included either ISCOMATRIX™ adjuvant (2 dosage levels), aluminum-hydroxide adjuvant, or were unadjuvanted, and were compared to phosphate-buffered saline placebo. Volunteers received 3 injections of assigned product on a 0, 1, 2 month schedule, and were followed for safety through 1 year after the last injection. Antibody levels were assessed at 6 time-points: enrollment, 28 days after each injection, and 6 and 12 months Postdose 3 (PD3). Of the 98 randomized participants, 90 (92%) received all 3 injections; 83 (85%) completed 1-year follow-up. Immunogenicity was measured by a qualified Focus Reduction Neutralization Test with a 50% neutralization cutoff (FRNT50). All 6 V180 formulations with ISCOMATRIX™ adjuvant showed robust immunogenicity, while the 1 aluminum-adjuvanted and 2 unadjuvanted formulations were poorly immunogenic. Geometric mean antibody titers generally declined at 6 months and 1 year PD3. All 9 V180 formulations were generally well tolerated. Formulations with ISCOMATRIX™ adjuvant were associated with more adverse events than aluminum-adjuvanted or unadjuvanted formulations.
|
Authors | Susan B Manoff, Michele Sausser, Amy Falk Russell, Jason Martin, David Radley, Donna Hyatt, Christine C Roberts, Jason Lickliter, Janakan Krishnarajah, Andrew Bett, Sheri Dubey, Tyler Finn, Beth-Ann Coller |
Journal | Human vaccines & immunotherapeutics
(Hum Vaccin Immunother)
Vol. 15
Issue 9
Pg. 2195-2204
( 2019)
ISSN: 2164-554X [Electronic] United States |
PMID | 30427741
(Publication Type: Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adjuvants, Immunologic
- Antibodies, Neutralizing
- Antibodies, Viral
- Dengue Vaccines
- Vaccines, Subunit
- Vaccines, Synthetic
|
Topics |
- Adjuvants, Immunologic
(administration & dosage)
- Adolescent
- Adult
- Antibodies, Neutralizing
(blood, immunology)
- Antibodies, Viral
(blood, immunology)
- Dengue
(prevention & control)
- Dengue Vaccines
(administration & dosage, immunology)
- Dengue Virus
- Drug Compounding
- Female
- Humans
- Immunization Schedule
- Immunogenicity, Vaccine
- Male
- Middle Aged
- Neutralization Tests
- Proof of Concept Study
- Vaccines, Subunit
(administration & dosage, immunology)
- Vaccines, Synthetic
(administration & dosage, immunology)
- Young Adult
|